期刊文献+

盐酸沃尼妙林预混剂在猪组织中残留消除规律研究 被引量:3

Studies on residues depletion of hydrochloride valnemulin premix in the porcine tissues
原文传递
导出
摘要 建立了猪肝脏、肾脏、肌肉和脂肪中盐酸沃尼妙林的高效液相色谱检测方法并研究盐酸沃尼妙林预混剂在猪体内各组织中的残留消除规律。对24头健康猪以200mg/kg的剂量混饲给药21d。在停药后0、6、12、18、24、36h分别宰杀4头猪,采集各组织进行药物残留测定。方法的检测限为0.025~0.062 5μg/g,定量限为0.05~0.1μg/g,肝脏的平均回收率为75.5%~76.4%,变异系数为2.3%~3.8%;肾脏的平均回收率为75.8%~78.5%,变异系数为4.1%~6.0%;肌肉的平均回收率为79.3%~80.0%,变异系数为3.0%~4.7%;脂肪的平均回收率为76.7%~77.3%,变异系数为3.3%~5.4%。结果表明,盐酸沃尼妙林在肝脏中残留量最高,肾脏其次;肌肉和脂肪中的残留量显著低于肝脏和肾脏,停药24h时,残留量低于定量限;停药36h时残留量均低至检测限以下。盐酸沃尼妙林预混剂在猪组织中消除迅速,建议休药期为2d。 To develop high performance liquid chromatography(HPLC) method of valnemulin hydrochloric residue in porcine tissues,and to explore elimination rule on its residues in the swine tissues.Twenty-four healthy pigs were administered valnemulin hydrochloric at a dosage of 200 mg/kg for 21 d.Four pigs were slaughtered at 0,6,12,18,24,36 h after the last feeding,respectively.Tissues including kidney,liver,muscle and fat of each pig were collected,and valnemulin of tissues were determined by high performance liquid chromatography(HPLC).The limit of detection(LOD) was 0.025-0.062 5 μg/g and the limit of quantification(LOQ) was 0.05-0.1 μg/g.The average recovery rate in liver was 75.5%-76.4% with coefficients of variation(CV) of 2.3%-3.8%;in kidney was 75.8%-78.5% with CV of 4.1%-6.0%;in muscle was 79.3%-80.0% with CV of 3.0%-4.7%;and in fat was 76.7%-77.3% with CV of 3.3%-5.4%.Results showed that the residues of valnemulin hydrochloric in liver was the highest,and lower in kidney.The residues of valnemulin hydrochloric in muscle and fat were much lower than that in liver and kidney,and was declined below the LOQ at 24 h,and dropped to LOD at 36 h of withdrawal period.The depletion of drugs in porcine tissues was fast.The withdrawal periods for all porcine tissues were 2.
出处 《中国兽医学报》 CAS CSCD 北大核心 2012年第2期272-276,共5页 Chinese Journal of Veterinary Science
关键词 盐酸沃尼妙林 高效液相色谱 猪组织 残留 消除 valnemulin hydrochloric HPLC porcine tissues residue depletion
  • 相关文献

参考文献10

  • 1EMEA. European Pharmacopoeia Commission, European Pharmacopoeia 5.4[S] :4043-4044.
  • 2EMEA. The european agency for the evaluation of me dicinal products, veterinary medicines evaluation unit: valnemulin, summary report[DB/OL]. Http ://www. emea. eu. int/pdfs/vet/mrls/O33998en, pdf, 1998.
  • 3EMEA. Econor, Valnemulin [ DB/OL]. Http://www. emea. europa, eu/vetdocs/pdfs/ epar/econor/ 003199en5. pdf,2004.
  • 4Stipkovits L, Ripley P H, Varga J, et al. Use of valne mulin in the control of mycoplasma infection under field conditions[J]. Vet Rec,2001,148(13) :399-402.
  • 5Jones M A,Gale C S,Roger P A,et al. Assessment of the efficacy of valnemulin premix in the treatment of naturally occur-ringoutbreaks of porcine proliferative enteropathy (PPE) under field conditions in the U. K [C]// Proceedings 18th International Pig Veterinary Society Congress Hamburg Germany in Press, 2004.
  • 6Morgan J H,Demarest H L,Burrows M R,et al. Model of colonic spirochaetosis for testing of Econor for prevention of disease [C] // Proeedings 17th International Pig Veterinary Society Congress Ames Iowa USA, 2002 : 142.
  • 7Berner H, Vyplel H. Pleuromutilin derivatives and their use[P]. EP :0153277,1985.
  • 8Poulsen S,Karlsson M,Johansson L,et al. The pleuromutilin drugs tiamulin and valnemulin bind to the RNA at the peptidyl transferase centre on the ribosome[J]. Mol Microbiol,2001,41(5) ; 1091-1099.
  • 9郭腾.动物专用抗生素类新药沃尼妙林研究进展[J].兽药与饲料添加剂,2003,8(5):8-11. 被引量:17
  • 10徐福亮,袁延文.介绍一种新的动物专用抗生素——盐酸沃尼妙林及其在猪病防治上的应用[J].中国动物保健,2005,7(12):40-42. 被引量:14

二级参考文献11

  • 1Stipkovits L, Ripley P H, Varga J, et al. Use of valnemulin in the control of mycoplasma bovis infection under field conditions [J]. Vet Rec,2001,148(13) :399 N 402.
  • 2Stipkovits L, Miller D, Glavits R, et al. Treatment of pigs experimentally infected with mycoplasma hyopneumoniae, pasteurella multocida, and actinobacillus pleuropneumoniae with various antibiotics [J]. Can J Vet Res,2001,65 (4) :213 - 222.
  • 3Norvatis. European field studies show effectiveness of econor in control of swine dysentery [DB/OL] . Http://www. econor. com , 2003.
  • 4EMEA. The european agency for the evaluation of medicinal products, veterinary medicines evaluation unit :valnemulin, summary report [DB/OL]Http://www. emea. eu. int/pdfs/vet/mrls/O33998en, pdf, 1998.
  • 5Karlsson M, Oxberry S, Hampson D. Antimierobiol susceptibility testing of Australian isolates of Braehyspira hyodysenteriae using a new broth dilution method [J] . Vet Microbio1,2002,84( 1 - 2) : 123 - 133.
  • 6Karlsson M, Gunnarsson A, Franklin A. Susceptibility to pleuromutilins in brachyspira (serpulina) hyodysenteriae[J]. Anim Health Rev,2001,2(1) :59 N65.
  • 7Berner H, Vyplel H. Pleuromutilin derivatives and theiruse [P]. EP:0153277,1985.
  • 8Poulsen S, Karlsson M, Johansson L, et al. The pleuromutilin drugs tiamulin and valnemulin bind to the RNA at the peptidyl transferase centre on the ribosome [J] . Mol Microbio1,2001,41 (5) : 1 091 - 1 099.
  • 9Koller K, Schwarz F. Formulation of valnemulin [ P ].US: 6284792,2001.
  • 10Hannan P C, Windsor H M, Ripley P H. In vitro susceptibilities of recent field isolates of mycoplasma hyopneumoniae and mycoplasma hyosynoviae to valnemulin(Econor), tiamulin and enrofloxacin and thein vitro development of resistance to certain antimicrobial agents in mycoplasma hyopneumoniae [J] . Res Vet Sci, 1997, 63(2) : 157 - 160.

共引文献26

同被引文献20

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部